Related Experiment Video
Updated: May 8, 2026
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Molecular Pathology of Lung Cancer
1Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Surgical Pathology Clinics
|May 6, 2026
Summary
Identifying genomic alterations is key for lung cancer treatment. Pathologists guide molecular testing to maximize the value of limited tissue samples for personalized therapy selection in non-small cell lung cancer (NSCLC).
Area of Science:
- Oncology
- Genomics
- Pathology
Background:
- Actionable genomic alterations are crucial for guiding lung cancer therapy selection.
- Molecular and biomarker testing in lung cancer is rapidly evolving.
- Pathologists are central to specimen selection, target identification, and methodology choice.
Purpose of the Study:
- To summarize the biomarker landscape in non-small cell lung cancer (NSCLC).
- To outline current recommendations for biomarker implementation.
- To provide strategies for maximizing the utility of limited NSCLC tissue samples.
Main Methods:
- Review of current literature and guidelines on lung cancer biomarkers.
- Analysis of the evolving role of pathologists in molecular testing.
- Discussion of techniques for optimizing tissue sample utilization.
Main Results:
- Genomic profiling is the standard of care for NSCLC treatment selection.
- Pathologists' expertise is vital for accurate and efficient molecular testing.
- Effective strategies can enhance the diagnostic and predictive value of limited tissue.
Conclusions:
- Optimizing biomarker testing in NSCLC requires a collaborative approach.
- Pathologists are essential in navigating the complexities of molecular diagnostics.
- Maximizing the value of limited tissue samples improves patient outcomes through targeted therapies.
